Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule ...Middle East

TÜBINGEN, Germany, Dec. 12, 2022 /PRNewswire/ -- Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary...

Hence then, the article about hearing loss company acousia therapeutics completes clinical phase 1 study with its small molecule was published today ( Monday 12/12/2022 - 12:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule )

Also on site :

• As Colorado’s wildfire threat grows, Douglas County turns to biochar as ‘next level’ mitigation tool
• Numbrix 9 - February 1
• Thousands of mutilated kids will sue ‘Mengele’ gender surgeons – Musk